Meagan Shields
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meagan Shields has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chad A. Bousman
University of Calgary
2 shared publications - Abdullah Al Maruf
University of Manitoba
1 shared publication - Adrian Box
Alberta Precision Laboratories, Calgary, AB T2N 4N1, Canada
1 shared publication - Amanda S. Newton
Department of Pediatrics, University of Alberta, Edmonton, Canada
1 shared publication Amanda Wondrasek
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada
1 shared publicationAmber Fryza
College of Pharmacy, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada
1 shared publication
Latest Publications
- Open Access
- 22 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 125
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial
Background: Treating depression and anxiety in adolescents can be challenging due to interindividual variability in medication response. With current trial-and-error prescribing practices, adolescents may undergo multiple medication changes over months or years before an effective and tolerated drug and dose are identified. Pharmacogenomic (PGx) testing can identify interindividual differences in drug metabolism, and evidence supporting PGx-guided prescribing in adults with mental disorders is growing. However, its impact on pediatric psychotropic prescribing remains underexplored. Methods: This is a protocol for a parallel-arm, multicentre, randomized controlled trial. Canadian adolescents aged 12–17 years who are initiating or switching a selective serotonin reuptake inhibitor (SSRI) for depression and/or an anxiety disorder under physician care are eligible. A total of 452 participants will be randomized 1:1 to PGx-guided SSRI prescribing (experimental) or SSRI prescribing based on current practice guidelines (control). Participants, caregivers, prescribing clinicians, outcome assessors, and investigators will be blinded to treatment allocation. Dual primary outcomes are symptom remission at 12 weeks, measured with the Quick Inventory of Depressive Symptomatology–Adolescent (QIDS-A17-SR) and the Screen for Child Anxiety Related Disorders (SCARED). Secondary outcomes, assessed at 4, 8, and 12 weeks, include participant- and physician-rated changes in depressive and anxiety symptoms, role functioning, health-related quality of life, health care utilization, cost-effectiveness, side-effect burden, medication burden, and adherence. Multiple testing will be addressed using the Hochberg method, and a parallel gated analysis will account for non-actionable genotypes. Secondary analysis will estimate minimal clinically important differences for symptom and role-functioning change with PGx-guided therapy. Discussion: At the time of writing, 36 participants have consented and been randomized to an intervention. This trial will evaluate whether PGx-guided prescribing improves symptom remission in adolescents treated with SSRIs. If efficacious, results should be interpreted with existing pediatric pharmacokinetic, observational, and adult trial data to inform PGx use in managing pediatric anxiety and depressive disorders.
- 22 February 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (2) , 125
Open AccessPharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial
Background: Treating depression and anxiety in adolescents can be challenging due to interindividual variability in medication response. With current trial-and-error prescribing practices, adolescents may undergo multiple medication changes over months or years before an effective and tolerated drug and dose are identified. Pharmacogenomic (PGx) testing can identify interindividual differences in drug metabolism, and evidence supporting PGx-guided prescribing in adults with mental disorders is growing. However, its impact on pediatric psychotropic prescribing remains underexplored. Methods: This is a protocol for a parallel-arm, multicentre, randomized controlled trial. Canadian adolescents aged 12–17 years who are initiating or switching a selective serotonin reuptake inhibitor (SSRI) for depression and/or an anxiety disorder under physician care are eligible. A total of 452 participants will be randomized 1:1 to PGx-guided SSRI prescribing (experimental) or SSRI prescribing based on current practice guidelines (control). Participants, caregivers, prescribing clinicians, outcome assessors, and investigators will be blinded to treatment allocation. Dual primary outcomes are symptom remission at 12 weeks, measured with the Quick Inventory of Depressive Symptomatology–Adolescent (QIDS-A17-SR) and the Screen for Child Anxiety Related Disorders (SCARED). Secondary outcomes, assessed at 4, 8, and 12 weeks, include participant- and physician-rated changes in depressive and anxiety symptoms, role functioning, health-related quality of life, health care utilization, cost-effectiveness, side-effect burden, medication burden, and adherence. Multiple testing will be addressed using the Hochberg method, and a parallel gated analysis will account for non-actionable genotypes. Secondary analysis will estimate minimal clinically important differences for symptom and role-functioning change with PGx-guided therapy. Discussion: At the time of writing, 36 participants have consented and been randomized to an intervention. This trial will evaluate whether PGx-guided prescribing improves symptom remission in adolescents treated with SSRIs. If efficacious, results should be interpreted with existing pediatric pharmacokinetic, observational, and adult trial data to inform PGx use in managing pediatric anxiety and depressive disorders.
- 20 March 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (4) , 175-186
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada
Objective: This work was designed to describe the knowledge and perceptions of pharmacogenomics (PGx) among pharmacists in the Canadian province of Manitoba. Methods: A 40-item, web-based survey wa... Tweetable abstract Manitoba pharmacists report positive perceptions toward pharmacogenomics (PGx). However, they are currently underprepared to implement PGx into practice, as evidenced by low self...
- 20 March 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (4) , 175-186
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada
Objective: This work was designed to describe the knowledge and perceptions of pharmacogenomics (PGx) among pharmacists in the Canadian province of Manitoba. Methods: A 40-item, web-based survey wa... Tweetable abstract Manitoba pharmacists report positive perceptions toward pharmacogenomics (PGx). However, they are currently underprepared to implement PGx into practice, as evidenced by low self...
- 1 July 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (7) , 3094-3118
Applications for pharmacogenomics in pharmacy practice: A scoping review
- 1 July 2022
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 18 (7) , 3094-3118
Applications for pharmacogenomics in pharmacy practice: A scoping review